Lung and Thymic Carcinoids

Christine L Hann; Patrick M Forde

doi:10.1016/j.ecl.2018.04.011

Lung and Thymic Carcinoids

Endocrinol Metab Clin North Am. 2018 Sep;47(3):699-709. doi: 10.1016/j.ecl.2018.04.011.

Authors

Christine L Hann¹, Patrick M Forde²

Affiliations

¹ Upper Aerodigestive Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. Electronic address: chann1@jhmi.edu.
² Upper Aerodigestive Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

PMID: 30098725
DOI: 10.1016/j.ecl.2018.04.011

Abstract

Carcinoids of the lung and thymus are rare thoracic cancers. In general, lung carcinoid tumors have a favorable prognosis, particularly when diagnosed at an early stage and treated with surgical resection. Thymic neuroendocrine tumors may be associated with multiple endocrine neoplasia-1 syndrome, tend to have a more aggressive natural history, and relatively frequently secrete ectopic adrenocorticotropic hormone.

Keywords: Carcinoid; Lung carcinoid; Lung neuroendocrine; Thymic carcinoid; Thymic neuroendocrine.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use
Carcinoid Tumor / drug therapy
Carcinoid Tumor / pathology
Carcinoid Tumor / surgery
Carcinoid Tumor / therapy*
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / pathology
Lung Neoplasms / surgery
Lung Neoplasms / therapy*
Neuroendocrine Tumors / drug therapy
Neuroendocrine Tumors / parasitology
Neuroendocrine Tumors / surgery
Neuroendocrine Tumors / therapy*
Thymus Neoplasms / drug therapy
Thymus Neoplasms / pathology
Thymus Neoplasms / surgery
Thymus Neoplasms / therapy*

Substances

Antineoplastic Agents